Cardiovascular outcomes associated with prescription of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with diabetes and chronic kidney disease

Feb 4, 2022Diabetes, obesity & metabolism

Heart and blood vessel outcomes linked to diabetes drugs SGLT2 inhibitors versus DPP-4 inhibitors in people with diabetes and kidney disease

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

New users of SGLT-2 inhibitors had a 23% lower risk of non-fatal myocardial infarction or stroke compared to DPP-4 inhibitors in patients with type 2 diabetes and no chronic kidney disease.

SGLT-2 inhibitors were associated with lower risks of heart failure hospitalization in patients with type 2 diabetes and no chronic kidney disease.
In patients with type 2 diabetes and chronic kidney disease stages 1-2, SGLT-2 inhibitors also showed a reduced risk of heart failure hospitalization.
No significant association between SGLT-2 inhibitors and heart failure hospitalization was observed in patients with chronic kidney disease stage 3a.
SGLT-2 inhibitors may suggest a benefit in reducing risk of non-fatal myocardial infarction or stroke in patients with type 2 diabetes, though this was not statistically significant in chronic kidney disease stages 1-2 and 3a.

AI simplified

AIM: To determine the association with cardiovascular (CV) outcomes of sodium-glucose co-transporter-2 (SGLT-2) inhibitors compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD).

MATERIALS AND METHODS: We conducted a population-based cohort study of new users of SGLT-2 inhibitors and DPP-4 inhibitors with T2D and CKD using data from Optum Clinformatics DataMart. We assembled three cohorts: T2D/no CKD, T2D/CKD 1-2, and T2D/CKD 3a. The study outcomes were (a) time to first heart failure (HF) hospitalization and (b) time to a composite CV endpoint comprised of non-fatal myocardial infarction (MI) or stroke. After inverse probability of treatment weighting, we used proportional hazards regression to estimate hazard ratios (HR) and 95% confidence intervals (CI).

RESULTS: New users of SGLT-2 inhibitors versus DPP-4 inhibitors had lower risks of HF hospitalization in the T2D/no CKD (HR, 0.76; 95% CI, 0.70, 0.82) and T2D/CKD 1-2 (HR, 0.63; 95% CI, 0.48, 0.84) cohorts, but no significant association was present in the T2D/CKD 3a cohort. Compared with prescription of DPP-4 inhibitors, SGLT-2 inhibitors were associated with lower risks of non-fatal MI or stroke of 23% (HR, 0.77; 95% CI, 0.70, 0.85) in the T2D/no CKD cohort, but no significant associations were present in the T2D/CKD 1-2 and T2D/CKD 3a cohorts.

CONCLUSIONS: Incident prescription of SGLT-2 inhibitors was associated with lower risks of HF hospitalization but not with non-fatal MI or stroke despite suggesting benefit, relative to prescription of DPP-4 inhibitor across different stages of CKD.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (XML) ↗View full text ↗

Cardiovascular outcomes associated with prescription of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with diabetes and chronic kidney disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief